Sodium ascorbate

SKU: orb1222741

Description

Ascorbate, also known as Ascorbicin, is a DNase I inhibitor. Ascorbate is an antioxidant which functions as a reducing agent and coenzyme in several metabolic pathways.(In Vitro):The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000.(In Vivo):Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs.After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.

Key Properties

• CAS Number: 134-03-2
• MW: 201.13
• Purity: >98% (HPLC)
• Formula: C₆H₈O₆·Na
• SMILES: [Na].[H][C@@]1(OC(=O)C(O)C1O)[C@@H](O)CO
• Target: 5-HT Receptor
• Solubility: H2O : ≥ 41 mg/mL; 206.96 mM

Bioactivity

• In Vivo:
  Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.
• In Vitro:
  The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5, 000.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Ascorbate | Sodium Ascorbate | Vitamin C sodium

Quick Database Links

Gene Symbol

5-HT Receptor